Stay updated on Mirvetuximab vs Bevacizumab in Ovarian Cancer Clinical Trial
Sign up to get notified when there's something new on the Mirvetuximab vs Bevacizumab in Ovarian Cancer Clinical Trial page.

Latest updates to the Mirvetuximab vs Bevacizumab in Ovarian Cancer Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoNo Change Detected
- Check16 days agoChange DetectedThe page’s revision/version indicator was updated from v3.5.2 to v3.5.3, reflecting a site software update rather than a change to the study record itself.SummaryDifference0.0%

- Check23 days agoChange DetectedAdded Revision: v3.5.2 and removed Revision: v3.5.0.SummaryDifference0.0%

- Check52 days agoChange DetectedThe page revision changed from v3.4.3 to v3.5.0.SummaryDifference0.0%

- Check66 days agoChange DetectedSite revision updated from v3.4.2 to v3.4.3.SummaryDifference0.0%

- Check74 days agoChange DetectedUpdated the study site list with many new locations and institutions, and removed several previously listed sites. The total number of locations is now 264.SummaryDifference3%

- Check88 days agoChange DetectedFallopian tube cancer was added to the Conditions list and a Genetic and Rare Diseases Information Center resource was linked in Resources. The page revision is updated to v3.4.2 from v3.4.1.SummaryDifference0.1%

Stay in the know with updates to Mirvetuximab vs Bevacizumab in Ovarian Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Mirvetuximab vs Bevacizumab in Ovarian Cancer Clinical Trial page.